Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome.

Ohanian M, Cable C, Halka K.

Clin Pharmacol. 2011;3:5-12. doi: 10.2147/CPAA.S17904. Epub 2011 May 24.

2.

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report.

Ohanian M, Cable C, Halka K.

Clin Pharmacol. 2011;3:45-50. doi: 10.2147/CPAA.S23687. Epub 2011 Nov 1.

3.

Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab.

Andries G, Karass M, Yandrapalli S, Linder K, Liu D, Nelson J, Pawar R, Chugh S.

Exp Hematol Oncol. 2017 Jan 13;6:4. doi: 10.1186/s40164-017-0064-7. eCollection 2017.

4.

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.

Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M.

J Med Case Rep. 2014 Sep 14;8:307. doi: 10.1186/1752-1947-8-307.

5.

Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.

Sevinc M, Basturk T, Sahutoglu T, Sakaci T, Koc Y, Ahbap E, Akgol C, Kara E, Brocklebank V, Goodship TH, Kavanagh D, Unsal A.

J Med Case Rep. 2015 Apr 29;9:92. doi: 10.1186/s13256-015-0575-y.

6.

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.

Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.

Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8.

PMID:
24021908
7.

Discontinuation of Peritoneal Dialysis after Late Initiation of Eculizumab in a Case of Familial Atypical Hemolytic-Uremic Syndrome: A Case Report.

Alonso Valente R, García Rodríguez GE, García Marcote Y, Fidalgo Díaz M, Becerra Mosquera V, Novoa García D, Cordal Martínez T, Díaz Rodríguez C.

Case Rep Nephrol Dial. 2017 Mar 2;7(1):18-25. doi: 10.1159/000457950. eCollection 2017 Jan-Apr.

8.

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V.

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):50-59. doi: 10.2215/CJN.06440616. Epub 2016 Oct 31.

PMID:
27799617
9.

Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome.

Yamada Y, Abe R, Okano Y, Miyakawa Y.

Intern Med. 2017;56(9):1085-1088. doi: 10.2169/internalmedicine.56.7862. Epub 2017 May 1.

10.

Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis.

Povey H, Vundru R, Junglee N, Jibani M.

Clin Nephrol. 2014 Nov;82(5):326-31. doi: 10.5414/CN107958.

PMID:
23557793
11.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

12.

Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab.

Sharma S, Pradhan M, Meyers KE, Le Palma K, Laskin BL.

Clin Nephrol. 2015 Sep;84(3):181-5. doi: 10.5414/CN108532.

13.

Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.

Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B.

Transplant Proc. 2010 Dec;42(10):4353-5. doi: 10.1016/j.transproceed.2010.09.125.

PMID:
21168697
14.

Effect of eculizumab and recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical hemolytic uremic syndrome due to anti-factor H autoantibodies.

Udagawa T, Motoyoshi Y, Matsumura Y, Takei A, Ariji S, Ito E, Chiga M, Nagasawa M, Morio T, Mizutani S.

CEN Case Rep. 2014 May;3(1):110-117. doi: 10.1007/s13730-013-0097-7. Epub 2013 Sep 12.

15.

Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.

Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J.

Pediatr Nephrol. 2012 Dec;27(12):2323-6. doi: 10.1007/s00467-012-2276-8. Epub 2012 Aug 14.

16.

Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome.

Vaughn JL, Moore JM, Cataland SR.

Case Rep Hematol. 2015;2015:327980. doi: 10.1155/2015/327980. Epub 2015 Oct 18.

17.

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.

J Thromb Haemost. 2014 Sep;12(9):1440-8. doi: 10.1111/jth.12615. Epub 2014 Jul 16.

18.

Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.

Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B.

Pediatrics. 2014 Jun;133(6):e1764-8. doi: 10.1542/peds.2013-1594.

19.

An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.

Sengul Samanci N, Ayer M, Ergen A, Ozturk S.

Transfus Apher Sci. 2015 Jun;52(3):314-6. doi: 10.1016/j.transci.2015.01.006. Epub 2015 Jan 12.

PMID:
25634788
20.

Eculizumab experience in an adult patient with atypical hemolytic uremic syndrome.

Sari F, Inci A, Karakus V, Yilmaz B, Sarikaya M, Olmaz R, Kurtoglu E.

Saudi J Kidney Dis Transpl. 2017 Mar-Apr;28(2):388-391. doi: 10.4103/1319-2442.202783.

Supplemental Content

Support Center